A case of obstructive sleep apnea syndrome improved by the administration of fluvoxamine
Version of Record online: 10 JUN 2003
Sleep and Biological Rhythms
Volume 1, Issue 2, pages 121–122, June 2003
How to Cite
HAYASHIDA, K., YAMADERA, W., SATO, M., OHBUCHI, K., OZONE, M., ITOH, H., SASAKI, M., USHIJIMA, S. and CHIBA, S. (2003), A case of obstructive sleep apnea syndrome improved by the administration of fluvoxamine. Sleep and Biological Rhythms, 1: 121–122. doi: 10.1046/j.1446-9235.2003.00017.x
- Issue online: 10 JUN 2003
- Version of Record online: 10 JUN 2003
- Accepted for publication 28 November 2002.
- selective serotonin re-uptake inhibitor;
- sleep apnea syndrome
This preliminary study intended to investigate the effects of a selective serotonin re-uptake inhibitor (SSRI) on obstructive sleep apnea syndrome (OSAS). The patient was diagnosed polysomnographically as having a moderate OSAS. He was administered 50 mg of fluvoxamine (FLV) for 1 week. After the drug administration, the changes in breathing and sleep parameters, and Epworth Sleepiness Scale (ESS) scores were examined. There was a pronounced improvement in the apnea–hypopnea index (AHI), mean and the lowest arterial oxygen saturation (SaO2), per cent of desaturation under 90%, and in the ESS scores. Therefore, we expected that SSRI may become a choice of treatment for patients with OSAS.